focus -WSS

focus

author：comprehensive 2025-09-27 23:01:00 - browse：85

A glass office building of MassMutual with its sign on the top left — insurance coverage from STAT — Adobe

One of the country’s biggest life insurers is venturing into genetic testing, an area that’s historically been a minefield for that industry, in a purported effort to keep its members alive longer.

MassMutual announced Tuesday that it’s offering many of its 4.2 million policyholders free genetic risk assessments for eight common diseases, like heart disease, type 2 diabetes, and breast cancer. The Springfield, Mass.-based insurer hopes that when people learn they carry a genetic predisposition, they’ll take action to lower their risk through diet, exercise, and getting regular screenings.

Viewed one way, it’s a win-win: The longer its members live, the longer MassMutual can collect and invest their premiums without paying out.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： CDC advisory group OKs chikungunya vaccine

WSS

As digital health tech proliferates, a new institute aims to cut through hype

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

'Vaccine

STAT Madness 2024: Meet the contenders

STAT Madness 2024: Meet the contenders

Custom gene therapy hints at new path for rare disease treatments

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

knowledge

Malaria cases in Florida and Texas: Here’s what you need to know

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

STAT Madness 2024: Meet the contenders

Bright Health sells Medicare Advantage business to Molina

WHO calls for emergency meeting on new China virus, as cases spread

At least 13 dead in Texas as scorching temps continue

Sanders adds drug shortage policies to pandemic preparedness bill

hotspot

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

In early work, researchers turn to CRISPR to treat Alzheimer's

Biden tests positive for Covid

Ohio train derailment: Experts on toxic chemical risks

Virtual repurposing can help discover new uses for existing drugs

hotspot

hotspot

hotspot

knowledge